Cargando…
New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
Multiple Sclerosis (MS) is an inflammatory and neurodegenerative disease of the central nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of disease-modifying drugs used for MS act on the inflammatory component of the disease and are approved for use in relap...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922247/ https://www.ncbi.nlm.nih.gov/pubmed/29719400 http://dx.doi.org/10.2147/NDT.S147874 |